Power Law company profile

Lyell Immunopharma

Biotech & Life Sciences · San Francisco, United States · Founded 2018 · IPO 2021 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$287M

Market cap · Apr/2026

Revenue

$36K

Latest reported FY

Investors

6 investors on Lyell Immunopharma's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 5 investors entered at this stage

8VC

ARCH Venture Partners

Bill & Melinda Gates Foundation

Arrive Roc Nation

Sahsen Ventures

Series B+ 1 investor entered at this stage

University of Washington

Global footprint

Where Lyell Immunopharma has talent and traffic

AI talent share

0.4% of workforce is AI talent
(1 of 226 staff)

Core AI00%

Other AI10.44%

Non-AI workforce22599.56%

Web traffic by country

11K monthly visits
across markets

🇺🇸 United States78.2%

🇮🇳 India18.2%

🏳️ Croatia2.7%

🇩🇪 Germany1.8%

Top 4 markets shown

Patent intelligence

$5M patent portfolio · 30 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.

Estimated portfolio value

$5M

1.6% of market cap · 436.3× smaller than top peer Ablynx ($2B)

30 active patent families

Where Lyell Immunopharma innovates Molecular biologyIMMUNOLOGIC CELLSCell biologyPotassium ionsBiochemistry

Below peer median on Strategic, Market

Quality vs same-sector peers

Lyell Immunopharma on the five Patsnap quality dimensions

Lyell Immunopharma in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.

Compare against

Patent quality scores (0–100)

Source: Dealroom Patent Intelligence · Patsnap

Tech-focus vs peers

Where Lyell Immunopharma concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Lyell Immunopharma and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Lyell Immunopharma on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo